Furthermore, recent studies have highlighted the mechanistic and potential therapeutic effects of adiponectin and adiporon, which are stimulators of adiponectin receptors, on AD through the activation of metabolic cascades such as the AdipoR1/AMPK and downstream insulin signaling pathways [14–17, 22]. This evidence concerns the gene ADIPOQ and Alzheimer disease.